US 10077311
Human antibodies to GFR alpha3 and methods of reducing pain associated with GFR alpha3-related diseases
granted A61KA61K2039/505A61K39/001103
Quick answer
US patent 10077311 (Human antibodies to GFR alpha3 and methods of reducing pain associated with GFR alpha3-related diseases) held by REGENERON PHARMACEUTICALS, INC. expires Mon Sep 13 2038 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.
Key facts
- Applicant
- REGENERON PHARMACEUTICALS, INC.
- Grant date
- Tue Sep 18 2018 00:00:00 GMT+0000 (Coordinated Universal Time)
- Expiration
- Mon Sep 13 2038 00:00:00 GMT+0000 (Coordinated Universal Time)
- Claims
- 10
- CPC classes
- A61K, A61K2039/505, A61K39/001103, A61K39/39533, A61K39/39541